SAB Biotherapeutics (SABS)
(Delayed Data from NSDQ)
$2.78 USD
+0.08 (2.79%)
Updated Jul 31, 2024 12:22 PM ET
After-Market: $2.84 +0.06 (2.33%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
08/19/2024
Time: -- |
6/2024 | $-1.13 | 0.00% |
Earnings Summary
For their last quarter, SAB Biotherapeutics (SABS) reported earnings of -$0.54 per share, beating the Zacks Consensus Estimate of $-0.98 per share. This reflects a positive earnings surprise of 44.90%. Look out for SABS's next earnings release expected on August 19, 2024. For the next earning release, we expect the company to report earnings of -$1.13 per share, reflecting a year-over-year increase of 19.29%.
Earnings History
Price & Consensus
Zacks News for SABS
Adma Biologics (ADMA) Reports Q1 Loss, Tops Revenue Estimates
SABS: What are Zacks experts saying now?
Zacks Private Portfolio Services